Couldbebetter
Two remarks, if I may:
First:
According to USPTO historical records, it takes on AVERAGE 22 months for PTO to grant a patent related to the pharmaceutical industry.
Amarin registered its first provisional patent application for LR-EtEPA on 26 January 2022. This is the date that counts for giving Amarin US patent priority claim.
According to USPTO rules a final so-called non-provisional application must be made within the 12-month non-extendable pendency period in order to preserve the validity of the initial priority claim date (26.01.2022).
In the absence of any official/non-official information in this regard, we assume this must have been done because Amarin applied for an International Patent Protection (IPT) for LR-EtEPA on 26 January 2023 based on all non-provisional US patent applications. Were the latter not valid the World Intellectual Property Organization (WIPO), which manages IPT, would not have been able to notify the 157 contracting States of Amarin’s application on 03 August 2023.
20 months have thus elapsed since US patent priority claim was established.
The above facts may explain why KM anticipated, in November 2022, announcing a significant update on FDC by the end of H2023! There indeed remain 2 months to reach the AVERAGE 22 months for USPTO pharmaceutical patent approval.
Hope such an event occurring in the next six months would constitute an important catalyst in Amarin’s life.
Secondly:
A. From TD COWEN PODCAST:
Yaron Werber:
Yeah. We’re going to move to my favorite part of the podcast. It’s a little personal touch and humor…. tell us one thing about you that no one knows. And it’s totally a secret, we’ll just keep it between the three of us.
Alex Denner:
Yeah. Well, I was going to just mention… Maybe this is a little bit more boring, but I love chemistry and I have kind of a home chemistry lab. I mean, nuclear engineering, chemistry, I spend a lot of time sort of, not related to experiments, not related to creating therapeutics, but I collect elements and I just find kind of elements in chemistry itself quite interesting. In our office… And both of you are welcome to come, and others I think have seen it, although it just got installed not that long before the pandemic, so maybe it is a secret. But we got a big periodic table, a large, large periodic table that’s actually made of… We have a cube that’s about so big of acrylic, and inside we have a sample of the element.
B. FROM Fierce Biotech:
Combining knowledge of the business with a clear connection to the science involved
Denner has created the template for the modern-day biotech turnaround story.
“Alex actually understands the science–and how to build that into a business,” ex-con and ImClone founder Sam Waksal told Bloomberg. “When a company is broken, he knows what should be done to fix it.”
As an inside player, few can compare to Denner. The big question now is where he plans to play next. And who will follow his game book on their own deals?
Article Written by John Carrol – Fierce Biotech
To read the entire list of the Most Influential People in Biopharama Visit Fierce Biotech
Best Regards.
Market Data 
Markets 
AI
